



1FW \$

CASE D0273 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name

Signature

9-28-06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: 9-28-06

Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652




CASE D0273 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name


Signature

7-28-06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1656

HUANG ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING
ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR
MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN
TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived, copies of the U.S. patent and U.S. patent publications are not submitted. Copies of foreign patent documents and non-patent literature, if cited, are enclosed

10/04/2006 WABDELRL 00000041 193880 10648593
01 FC:1806 180.00 DA

In accordance with 37 C.F.R. § 1.98(a)(2)(iii), applicants wish to call the Examiner's attention to the following related applications:


Attorney Docket No.	Application No.	Filing Date	Status
D0185 NP	10/348,119	1/17/03	Pending
10001 NP	11/169,041	6/28/05	Pending

Copies of these references are also enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289




Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 9-28-06

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
	AA	10/348,119	1/17/03	Huang, et al.			
	AB	11/169,041	6/28/05	Huang, et al.			

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
	AC	2006/0029971 A1	2/9/06	Golub, et al.			
	AD	2005/0079518 A1	4/14/05	Baker, et al.			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AG	WO00/62778	10/26/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AL	Aasheim, et al., "A Splice Variant of Human Ephrin-A4 Encodes a Soluble Molecule that is Secreted by Activated Human B Lymphocytes", Blood, Vol. 95(1), pp. 221-230 (2000)
	AM	Abraham, et al., "Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder", Clin. Cancer Res., Vol. 12(2), pp. 353-360 (2006)
	AN	Alves, et al., "EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes", Cancer Res., Vol. 63, pp. 8476-8480 (2003)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003

Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Blume-Jensen, et al., "Oncogenic Kinase Signalling", Nature, Vol. 411, pp. 355-365 (2001)
2AB	Brantley, et al., "Soluble Eph A Receptors Inhibit Tumor Angiogenesis and Progression <i>in vivo</i> ", Oncogene, Vol. 21, pp. 7011-7026 (2002)
2AC	Brown, et al., "Regulation, Substrates and Functions of SRC", Biochimica et Biophys. Acta., Vol. 1287, pp. 121-149 (1996)
2AD	Cheng, et al., "Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis", Molec. Cancer Res., Vol. 1, pp. 2-11 (2002)
2AE	Davis, et al., "Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity", Science, Vol. 266, pp. 816-819 (1994)
2AF	de Saint-Vis, et al., "Human Dendritic Cells Express Neuronal Eph Receptor Tyrosine Kinases: Role of EphA2 in Regulating Adhesion to Fibronectin", Blood, Vol. 102(13), pp. 4431-4440 (2003)
2AG	Duxbury, et al., "Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness", Biochem. Biophysical Res. Comm., Vol. 320, pp. 1096-1102 (2004)
2AH	Fang, et al., "A Kinase-Dependent Role for EphA2 Receptor in Promoting Tumor Growth and Metastasis", Oncogene, Vol. 24, pp. 7859-7868 (2005)
2AI	Flanagan, et al., "The Ephrins and EPH Receptors in Neural Development", Annu. Rev. Neurosci, Vol. 21, pp. 309-45 (1998)
2AJ	Frame, M.C., "Src in Cancer: Deregulation and Consequences for Cell Behaviour", Biochimica et Biophys. Acta, Vol. 1602, pp. 114-130 (2002)
2AK	Gale, et al., "Eph Receptors and Ligands Comprise Two Major Specificity Subclasses and Are Reciprocally Compartmentalized during Embryogenesis", Neuron, Vo. 17, pp. 9-19 (1996)
2AL	Ganju, et al., "The Eck Receptor Tyrosine Kinase is Implicated in Pattern Formation during Gastrulation, hindbrain segmentation and limb development", Oncogene, Vol. 9, pp. 1613-1624 (1994)
2AM	Goldman-Wohl, et al., "Eph and Ephrin Expression in Normal Placental Development and Preeclampsia", Placenta, Vol. 25, pp. 623-630 (2004)
2AN	Herath, et al., "Over-Expression of Eph and Ephrin Genes in Advanced Ovarian Cancer: Ephrin Gene Expression Correlates with Shortened Survival", BMC Cancer, Vol. 6, pp. 144 (2006)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Herrem, et al., "Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma", Vol. 11, pp. 226-231 (2005)
3AB	Hess, et al., "VE-Cadherin Regulates EphA2 in Aggressive Melanoma Cells Through a Novel Signaling Pathway", Cancer Biol. Therapy, Vol. 5(2), pp. 228-233 (2006)
3AC	Holder, et al., "Eph Receptors and Ephrins: Effectors of Morphogenesis", Development, Vol. 126, pp. 2033-2044 (1999)
3AD	Hu, et al., "EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells", Mol Cancer Res., Vol. 2(10), pp. 533-540 (2004)
3AE	Hynes, N.E., "Tyrosine Kinase Signalling in Breast Cancer", Breast Cancer Res., Vol. 2, pp. 154-157 (2000)
3AF	Kalo, et al., "Signal Transfer by Eph Receptors", Cell Tissue Res., Vol. 298, pp. 1-9 (1999)
3AG	Kataoka, et al., "Correlation of EPHA2 Overexpression with High Microvessel Count in Human Primary Colorectal Cancer", Cancer Sci., Vol. 95(2), pp. 136-141 (2004)
3AH	Kikawa, et al., "Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation", J. Biol. Chem., Vol. 277(42), pp. 39274-39279 (2002)
3AI	Kinch, et al., "Overexpression and Functional Alterations of the EphA2 Tyrosine Kinase in Cancer", Clin. Exper. Metastasis, Vol. 20, pp. 59-68 (2003)
3AJ	Kinch, et al., "Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival", Clin. Cancer Res., Vol. 9, pp. 613-618 (2003)
3AK	Koolpe, et al., "An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor", J. Biol. Chem., vol. 277(49), pp. 46974-46979 (2002)
3AL	Kozlosky, et al., "Lerk-7: A Ligand of the Eph-Related Kinases is Developmentally Regulated in the Brain", Cytokine, Vol. 9(8), pp. 540-549 (1997)
3AM	Lindberg, et al., "cDna Cloning and Characterization of <i>eck</i> , an Epithelial Cell Receptor Protein-Tyrosine Kinase in the <i>eph/elk</i> Family of Protein Kinases", Molec. Cell. Biol., Vol. 10(12), pp. 6316-6324 (1990)
3AN	Lombardo, et al., "Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays", J. Med. Chem., Vol. 47, pp. 6658-6661 (2004)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	Lu, et al., "EphA2 Overexpression Decreases Estrogen Dependence and Tamoxifen Sensitivity", Cancer Res., Vol. 63, pp. 3425-3429 (2003)
4AB	Macrae, et al., "A Conditional Feedback Loop Regulates Ras Activity Through EphA2", Cancer Cell, Vol. 8, pp. 111-118 (2005)
4AC	Miao, et al., "Activation of EphA2 Kinase Suppresses Integrin Function and Causes Focal-Adhesion-Kinase Dephosphorylation", Nature Cell Biol., Vol. 2, pp. 62-69 (2000)
4AD	Miyazaki, et al., "EphA2 Overexpression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma", Int. J. Cancer, Vol. 103, pp. 657-663 (2003)
4AE	Nakamoto, et al., "Diverse Roles for the Eph Family of Receptor Tyrosine Kinases in Carcinogenesis", Microscopy Research Tech., Vol. 59, pp. 58-67 (2002)
4AF	Nakamura, et al., "Epha2/Efna1 Expression in Human Gastric Cancer", Cancer Sci., Vol. 96(1), pp. 42-47 (2005)
4AG	Ogawa, et al., "The Ephrin-A1 Ligand and its Receptor, EphA2, are Expressed during Tumor Neovascularization", Oncogene, Vol. 19, pp. 6043-6052 (2000)
4AH	Paik, et al., "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer", New Eng. J. Med., Vol. 351(27), pp. 2817-2826 (2004)
4AI	Pandey, et al., "Characterization of a Novel Src-like Adapter Protein That Associates with the Eck Receptor Tyrosine Kinase", Vol. 270(33), pp. 19201-19204 (1995)
4AJ	Pandey, et. al., "Activation of the Eck Receptor Protein Tyrosine Kinase Stimulates Phosphatidylinositol 3-Kinase Activity", J. Biol. Chem., Vol. 269(48), pp. 30154-30157 (1994)
4AK	Pandey, et. al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis", Science, Vol. 268, pp. 567-569 (1995)
4AL	Parri, et. al., "EphrinA1 Repulsive Response is Regulated by an EphA2 Tyrosine Phosphatase", J. Biol. Chem., Vol. 280(40), pp. 34008-34018 (2005)
4AM	Pratt, et al., "Activation of the EphA2 Tyrosine Kinase Stimulates the MAP/ERK Kinase Signaling Cascade", Oncogene, Vol. 21, pp. 7690-7699 (2002)
4AN	Riss, et al., "Comparison of MTT, XTT, and Novel Letrazollum Compound MTS for In Vitro Proliferation and Chamosensitivity Assays", Mol. Biol. Cell, 3 (Suppl):184(a).

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	5AA	Ruiz, et al., "The Expression of the Receptor-Protein Tyrosine Kinase Gene, <i>Eck</i> , is Highly Restricted during Early Mouse Development", Mechanisms Develop., Vol. 46, pp. 87-100 (1994)
	5AB	Saito, et al., "Expression of EphA2 and E-Cadherin in Colorectal Cancer: Correlation with Cancer Metastasis", Oncology Rep., Vol. 11, pp. 605-61 (2004)
	5AC	Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, /First and Second Edition, Book 1, Cold Spring Harbor Laboratory Press, publ., pp. 1.93-1.104 (1989)
	5AD	Sulman, et al., "ECK, a Human EPH-Related Gene, Maps to 1p36.1, a Common Region of Alteration in Human Cancers", Genomics, Vol. 40, pp. 371-374 (1997)
	5AE	Tanaka, et al., "EphA2 Phosphorylates the Cytoplasmic Tail of Claudin-4 and Mediates Paracellular Permeability", J. Biol. Chem., Vol. 280(51), pp. 42375-42382 (2005)
	5AF	Thaker, et al., "EphA2 Expression is Associated with Aggressive Features in Ovarian Carcinoma", Clin. Cancer Res., Vol. 10, pp. 5145-5150 (2004)
	5AG	Walker-Daniels, et al., "Differential Regulation of EphA2 in Normal and Malignant Cells", Amer. J. Path., Vol. 162(4), pp. 1037-1042 (2003)
	5AH	Walker-Daniels, et al., "C-Cbl-Dependent EphA2 Protein Degradation is Induced by Ligand Binding", Molecular Cancer Res., Vol. 1, pp. 79-87 (2002)
	5AI	Wands, et al., "High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB _s Ag) Produced by Somatic Cell Hybrids", Gastroenterology, Vol. 80, pp. 225-32 (1981)
	5AJ	Wang, et al., "Negative Regulation of EphA2 Receptor by Cbl", Biochem. Biophys. Res. Comm., Vol. 296, pp. 214-220 (2002)
	5AK	Wilkinson, D.G., "Eph Receptors and Ephrins: Regulators of Guidance and Assembly", International Rev. Cytology, Vol. 196, pp. 177-244 (2000)
	5AL	Wilkinson, D.G., "Multiple Roles of EPH Receptors and Ephrins in Neural Development", Vol. 2, pp. 155-164 (2001)
	5AM	Xu, et al., "EphA2: Expression in the Renal Medulla and Regulation by Hypertonicity and Urea Stress In Vitro and In Vivo", Am. J. Physiol. Renal Physiol, Vol. 288, pp. F855-F866 (2005)
	5AN	Xu, et al., "Roles of Eph Receptors and Ephrins in Segmental Patterning", Phil. Trans. R. Soc. Lond., B., Vol. 355, pp. 993-1002 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003

Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Yong, et al., "Molecular Profiling of CD34+ Cells Identifies Low Expression of CD7, Along with High Expression of Proteinase 3 or Elastase, as Predictors of Longer Survival in Patients with CML", Blood, Vol. 107(1), pp. 205-212 (2006)
6AB	Zelinski, et al., "Estrogen and Myc Negatively Regulate Expression of the EphA2 Tyrosine Kinase", J. Cell. Biochem., Vol. 85, pp. 714-720 (2002)
6AC	Zeng, et al., "High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia", Amer. J. Path., Vol. 163(6), pp. 2271-2276 (2003)
6AD	Zhou, R., "The Eph Family Receptors and Ligands", Pharmacol. Ther., Vol. 77(3), pp. 151-181 (1998)
6AE	NCBI Entrez Accession No. NM_004431 (gi:32967310), Hess, et al., August 13, 2006
6AF	
6AG	
6AH	
6AI	
6AJ	
6AK	
6AL	
6AM	
6AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.